secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001999371-25-018430
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Pharma receives FDA IND clearance for TNX-102 SL Phase 2 MDD study
------------------------------------------------------------------------

- FDA cleared IND for TNX-102 SL (cyclobenzaprine HCl) 5.6 mg sublingual tablets to treat major depressive disorder in adults.
- Potentially pivotal Phase 2 HORIZON study: 6-week, randomized, double-blind, placebo-controlled, 360 patients at ~30 U.S. sites.
- Primary endpoint: MADRS total score change from baseline at Week 6; enrollment to begin mid-2026.
- TNX-102 SL targets disrupted sleep associated with MDD; prior fibromyalgia and PTSD studies showed depression symptom improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125018430/0001999371-25-018430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125018430/tnxp-8k_112425.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-018430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer